PD-L1 was used as the myeloid-targeting moiety as it is highly expressed in CD45+ CD11b+ TAMCs over CD45+CD11b- tumor-infiltrating lymphocytes (TILs) and tumor cells (Fig. 2d, Supplementary Fig. 1b). This evidence concerns the gene PTPRC and neoplasm.